Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation-Reference-Cited by-同舟云学术

Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation

Published:2013-09 Issue:9 Volume:19 Page:1381-1386
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Russell James A.,Kangarloo Shahbal B.,Williamson Tyler,Chaudhry M. Ahsan,Savoie Mary Lynn,Turner A. Robert,Larratt Loree,Storek Jan,Bahlis Nizar J.,Shafey Mona,Brown Christopher B.,Yang Maggie,Geddes Michelle,Zacarias Nancy,Yue Ping,Duggan Peter,Stewart Douglas A.,Daly Andrew

Funder

Otsuka Pharma

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference26 articles.

1. Therapeutic drug monitoring of busulfan in transplantation;Russell;Curr Pharm Des,2008

2. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total-body irradiation, and thymoglobulin;Russell;Biol Blood Marrow Transplant,2007

3. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes;Russell;Biol Blood Marrow Transplant,2002

4. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched-pair analysis;Russell;Biol Blood Marrow Transplant,2007

5. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS;de Lima;Blood,2004

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

3. Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders;Pediatric Blood & Cancer;2023-04-12

4. Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR;European Journal of Haematology;2022-12

5. The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study;Frontiers in Pharmacology;2022-06-16